SCHEMBL2534684

SCHEMBL2534684

O=C(Nc1nc2ccc(Sc3nnc4ccccn34)cc2s1)C1CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 5/20 0.60
CASP3 P42574 1/20 0.52
SENP8 Q96LD8 1/20 0.52
SENP7 Q9BQF6 1/20 0.52
SENP6 Q9GZR1 1/20 0.52
NPC1 O15118 4/20 0.49
RAB9A P51151 4/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
HSP90AA1 P07900 1/20 0.48
MAOA P21397 1/20 0.47
MAOB P27338 1/20 0.47
GFER P55789 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
ABL1 P00519 3/20 0.46
LCK P06239 2/20 0.46
CYP3A4 P08684 1/20 0.46
DYRK1A Q13627 1/20 0.46
LMNA P02545 1/20 0.45
MAPK1 P28482 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2533142 0.84 CASP3 (0.51) METCASP3SENP8SENP7SENP6
SCHEMBL2540564 0.82 MET (0.73) METCASP3SENP8SENP7SENP6
SCHEMBL2541449 0.82 MET (0.66) METCASP3SENP8SENP7SENP6
SCHEMBL2534661 0.80 MET (0.59) MET
SCHEMBL1581446 0.79 MET (0.53) METSMN1; SMN2ABL1CYP3A4ALDH1A1
SCHEMBL2549710 0.79 MET (0.73) METCASP3SENP8SENP7SENP6
SCHEMBL2542908 0.79 MET (0.63) METCASP3SENP8SENP7SENP6
SCHEMBL2540286 0.79 MET (0.60) METCASP3SENP8SENP7SENP6
SCHEMBL3726507 0.79 MET (0.67) METCASP3SENP8SENP7SENP6
SCHEMBL1581382 0.79 MET (0.64) METABL1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110263594-A1 NOVEL TRIAZOLO(4,3-A)PYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE, IN PARTICULAR AS MET INHIBITORS SANOFI-AVENTIS (FR) 2011-10-27 US claimed
US-20110263594-A1 NOVEL TRIAZOLO(4,3-A)PYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE, IN PARTICULAR AS MET INHIBITORS SANOFI-AVENTIS (FR) 2011-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263594-A1 NOVEL TRIAZOLO(4,3-A)PYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE, IN PARTICULAR AS MET INHIBITORS MET, RET, ALK MET 1/4885CASP3 2245/4885SENP8 3536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.